person · Reporting owner

SIGAL ELLIOT

Disclosed activity across 3 companies

Tapewire entity: 16624
SEC CIK: 0001202294

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BRISTOL MYERS SQUIBB COBMY · Entity 1662	Director · EVP, CSO & President R&D	June 03, 2013	June 05, 2013

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date June 03, 2013 · Filed June 05, 2013

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	148,221	Ending reported balance After 2013-06-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2013-06-03 · Exercise / conversion · Acquired 98,875 · Balance 231,868 Row 2 · 2013-06-03 · Sale · Disposed 83,647 · Balance 148,221 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.83 to $48.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.01 · Expires 2017-03-05	Direct	25,000	Reported balance After 2013-06-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2013-06-03 · Exercise / conversion · Disposed 98,875 · Balance 25,000 F3: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBy BMY Savings & Investment Program	1,628.06	Reported balance Holding disclosure · report date 2013-06-03 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,628.06 F2: Based on a plan statement as of the end of the most recent fiscal quarter.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBy C. Elliott Sigal 2012 Irrevocable Trust	18,180	Reported balance Holding disclosure · report date 2013-06-03 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 18,180
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBy Ruth L. Sigal Irrevocable Trust	18,180	Reported balance Holding disclosure · report date 2013-06-03 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 18,180
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBy Sigal Family Investments, LLC	9,091	Reported balance Holding disclosure · report date 2013-06-03 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 9,091

Filing footnotes · ownership attribution and instrument terms

F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.83 to $48.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

F2: Based on a plan statement as of the end of the most recent fiscal quarter.

F3: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Mead Johnson Nutrition Co

Report date June 15, 2017 · Filed June 15, 2017

Section 16 reporting ended · disclosed 2017-06-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-06-15 transaction · row 1 1 source row Row 1 · 2017-06-15 · Disposition to issuer · Disposed 13,721 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.
Common StockSEC Table I · non-derivative	IndirectBy Sigal Family Investments, LLC	Reported balance After 2017-06-15 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-06-15 · Disposition to issuer · Disposed 2,590 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.
Common StockSEC Table I · non-derivative	IndirectBy the C. Elliott Sigal 2012 Irrevocable Trust	Reported balance After 2017-06-15 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-06-15 · Disposition to issuer · Disposed 5,180 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.
Common StockSEC Table I · non-derivative	IndirectBy the Ruth L. Sigal 2012 Irrevocable Trust	Reported balance After 2017-06-15 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2017-06-15 · Disposition to issuer · Disposed 5,180 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-06-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-06-15 · Disposition to issuer · Disposed 1,709 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock. F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock.

F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share.

Spark Therapeutics, Inc.

Report date December 17, 2019 · Filed December 17, 2019

Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-12-17 transaction · row 1 1 source row Row 1 · 2019-12-17 · Other · Disposed 14,214 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29	Direct	Reported balance After 2019-12-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30	Direct	Reported balance After 2019-12-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31	Direct	Reported balance After 2019-12-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-08-11	Direct	Reported balance After 2019-12-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-12-17 · Disposition to issuer · Disposed 17,203 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-06-10	Direct	Reported balance After 2019-12-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-12-17 · Disposition to issuer · Disposed 25,786 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 17, 2019 Filed Dec 17, 2019 16:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	25,786	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0000899243-19-029447 · doc4.xml · derivative · entry 6 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,786 shares Expires 2024-06-10 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 16:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	17,203	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0000899243-19-029447 · doc4.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,203 shares Expires 2024-08-11 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 16:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $56.22	$0.00	Disclosure SEC source: 0000899243-19-029447 · doc4.xml · derivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-05-31 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 16:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $50.93	$0.00	Disclosure SEC source: 0000899243-19-029447 · doc4.xml · derivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2027-05-30 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 16:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $81.53	$0.00	Disclosure SEC source: 0000899243-19-029447 · doc4.xml · derivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2028-05-29 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 16:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	OtherCommon Stock	14,214	$114.50	$1,627,503.00	Disclosure SEC source: 0000899243-19-029447 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. Read SEC document
May 30, 2019 Filed Jun 3, 2019 16:19 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	1,500	$0.00	$0.00	Disclosure SEC source: 0001609351-19-000060 · wf-form4_155959314981908.xml · derivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. Read SEC document
May 30, 2019 Filed Jun 3, 2019 16:19 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	1,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-19-000060 · wf-form4_155959314981908.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document
May 31, 2018 Filed May 31, 2018 21:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	1,500	$0.00	$0.00	Disclosure SEC source: 0001609351-18-000050 · wf-form4_152781563763708.xml · derivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F5 · derivative.exercise_date: On May 31, 2017, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. F5 · derivative.expiration_date: On May 31, 2017, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. Read SEC document
May 31, 2018 Filed May 31, 2018 21:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	1,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-18-000050 · wf-form4_152781563763708.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document
May 30, 2018 Filed May 31, 2018 21:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantStock Option (right to buy) · Derivative	4,000	$0.00 Strike: $81.53	$0.00	Disclosure SEC source: 0001609351-18-000050 · wf-form4_152781563763708.xml · derivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2028-05-29 F4 · derivative.exercise_date: 100% of the shares vest on the one-year anniversary of the grant date. Read SEC document
May 30, 2018 Filed May 31, 2018 21:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	1,500	$0.00	$0.00	Disclosure SEC source: 0001609351-18-000050 · wf-form4_152781563763708.xml · derivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document
November 28, 2017 Filed Apr 16, 2018 17:49 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	29	$72.43	$2,100.47	Disclosure SEC source: 0001609351-18-000028 · wf-form4_152391529825009.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,214 F1 · acquired: Reflects transactions occurring in a brokerage account managed by an investment advisor who maintained discretionary authority over the account. The transactions were made by the investment advisor in contradiction of the Reporting Person's instructions and without the Reporting Person's approval. Read SEC document
October 12, 2017 Filed Apr 16, 2018 17:49 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	PurchaseCommon Stock	29	$90.75	$2,631.75	Disclosure SEC source: 0001609351-18-000028 · wf-form4_152391529825009.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,243 F1 · acquired: Reflects transactions occurring in a brokerage account managed by an investment advisor who maintained discretionary authority over the account. The transactions were made by the investment advisor in contradiction of the Reporting Person's instructions and without the Reporting Person's approval. Read SEC document
June 15, 2017 Filed Jun 15, 2017 15:46 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	Disposition to issuerRestricted Stock Units · Derivative	1,709	$90.00	$153,810.00	Disclosure SEC source: 0001104659-17-039520 · a4.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,709 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock. F3 · price: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. F3 · derivative.exercise_date: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. F3 · derivative.expiration_date: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. Read SEC document
June 15, 2017 Filed Jun 15, 2017 15:46 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	Disposition to issuerCommon Stock	5,180	$90.00	$466,200.00	Disclosure SEC source: 0001104659-17-039520 · a4.xml · nonDerivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Ruth L. Sigal 2012 Irrevocable Trust Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. Read SEC document
June 15, 2017 Filed Jun 15, 2017 15:46 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	Disposition to issuerCommon Stock	5,180	$90.00	$466,200.00	Disclosure SEC source: 0001104659-17-039520 · a4.xml · nonDerivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the C. Elliott Sigal 2012 Irrevocable Trust Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. Read SEC document
June 15, 2017 Filed Jun 15, 2017 15:46 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	Disposition to issuerCommon Stock	2,590	$90.00	$233,100.00	Disclosure SEC source: 0001104659-17-039520 · a4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Sigal Family Investments, LLC Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. Read SEC document
June 15, 2017 Filed Jun 15, 2017 15:46 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	Disposition to issuerCommon Stock	13,721	$90.00	$1,234,890.00	Disclosure SEC source: 0001104659-17-039520 · a4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. Read SEC document
May 31, 2017 Filed Jun 2, 2017 16:06 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	1,500	$0.00	$0.00	Disclosure SEC source: 0001609351-17-000050 · wf-form4_149643399237232.xml · derivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document
May 31, 2017 Filed Jun 2, 2017 16:06 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantStock Option (right to buy) · Derivative	4,000	$0.00 Strike: $50.93	$0.00	Disclosure SEC source: 0001609351-17-000050 · wf-form4_149643399237232.xml · derivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2027-05-30 F1 · derivative.exercise_date: 100% of the shares vest on the one-year anniversary of the grant date. Read SEC document
March 01, 2017 Filed Mar 2, 2017 10:28 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,373	$0.00	$0.00	Disclosure SEC source: 0001209191-17-016278 · doc4.xml · derivative · entry 6 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,373 shares Expires 2017-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F2 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. Read SEC document
March 01, 2017 Filed Mar 2, 2017 10:28 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	Exercise / conversionCommon Stock	2,373	$0.00	$0.00	Disclosure SEC source: 0001209191-17-016278 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 28, 2017 Filed Mar 2, 2017 10:28 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	GrantRestricted Stock Unit (RSU) · Derivative	1,709	$0.00	$0.00	Disclosure SEC source: 0001209191-17-016278 · doc4.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,709 Underlying: Common Stock · 1,709 shares Expires 2018-02-28 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. F2 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. Read SEC document
June 03, 2013 Filed Jun 5, 2013 20:28 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionExecutive Option (right to buy) · Derivative	98,875	$0.00 Strike: $27.01	$0.00	Disclosure SEC source: 0001225208-13-013978 · doc4.xml · derivative · entry 7 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, $0.10 par value · 98,875 shares Expires 2017-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007. F3 · derivative.expiration_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007. Read SEC document
June 03, 2013 Filed Jun 5, 2013 20:28 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	83,647	$48.18	$4,030,112.46	Disclosure SEC source: 0001225208-13-013978 · doc4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,221 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.83 to $48.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
June 03, 2013 Filed Jun 5, 2013 20:28 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	98,875	$27.01	$2,670,613.75	Disclosure SEC source: 0001225208-13-013978 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 30, 2013 Filed May 31, 2013 22:14 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionExecutive Option (right to buy) · Derivative	50,000	$0.00 Strike: $24.74	$0.00	Disclosure SEC source: 0001225208-13-013595 · doc4.xml · derivative · entry 9 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 50,000 shares Expires 2016-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-third of the stock option award vested on each of the third, fourth and fifth anniversaries of the grant date, which was December 1, 2006. F4 · derivative.expiration_date: One-third of the stock option award vested on each of the third, fourth and fifth anniversaries of the grant date, which was December 1, 2006. Read SEC document
May 30, 2013 Filed May 31, 2013 22:14 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionExecutive Option (right to buy) · Derivative	120,625	$0.00 Strike: $27.01	$0.00	Disclosure SEC source: 0001225208-13-013595 · doc4.xml · derivative · entry 8 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,875 Underlying: Common Stock, $0.10 par value · 120,625 shares Expires 2017-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007. F3 · derivative.expiration_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007. Read SEC document
May 30, 2013 Filed May 31, 2013 22:14 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	143,521	$47.23	$6,778,496.83	Disclosure SEC source: 0001225208-13-013595 · doc4.xml · nonDerivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,993 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.15 to $47.43, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
May 30, 2013 Filed May 31, 2013 22:14 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	50,000	$24.74	$1,237,000.00	Disclosure SEC source: 0001225208-13-013595 · doc4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 30, 2013 Filed May 31, 2013 22:14 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	120,625	$27.01	$3,258,081.25	Disclosure SEC source: 0001225208-13-013595 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionExecutive Option (right to buy) · Derivative	202,405	$0.00 Strike: $24.74	$0.00	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · derivative · entry 24 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, $0.10 par value · 202,405 shares Expires 2016-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: One-third of the stock option award vested on each of the third, fourth and fifth anniversaries of the grant date, which was December 1, 2006. F9 · derivative.expiration_date: One-third of the stock option award vested on each of the third, fourth and fifth anniversaries of the grant date, which was December 1, 2006. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionExecutive Option (right to buy) · Derivative	103,500	$0.00 Strike: $25.45	$0.00	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · derivative · entry 23 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 103,500 shares Expires 2015-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third and fourth anniversaries of the grant date, which was March 1, 2005. F10 · derivative.expiration_date: Twenty-five percent of the stock option award vested on each of the first, second, third and fourth anniversaries of the grant date, which was March 1, 2005. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	459	$39.65	$18,199.35	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 18 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Sigal Family Investments, LLC Disclosed balance after: 9,091 Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	919	$39.65	$36,438.35	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 16 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Ruth L. Sigal Irrevocable Trust Disclosed balance after: 18,180 F6 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	919	$39.65	$36,438.35	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 14 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By C. Elliott Sigal 2012 Irrevocable Trust Disclosed balance after: 18,180 F6 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	175,143	$39.61	$6,937,414.23	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 12 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,889 F1 · shares: Includes shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. F4 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.60 to $39.67, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	90,234	$39.61	$3,574,168.74	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 11 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,032 F1 · shares: Includes shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. F4 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.60 to $39.67, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	88,132	$39.63	$3,492,671.16	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 10 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,266 F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.62 to $39.65, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	103,500	$25.45	$2,634,075.00	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 9 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 30, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	202,405	$24.74	$5,007,499.70	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 8 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 29, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionExecutive Option (right to buy) · Derivative	36,503	$0.00 Strike: $24.74	$0.00	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · derivative · entry 22 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,405 Underlying: Common Stock, $0.10 par value · 36,503 shares Expires 2016-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: One-third of the stock option award vested on each of the third, fourth and fifth anniversaries of the grant date, which was December 1, 2006. F9 · derivative.expiration_date: One-third of the stock option award vested on each of the third, fourth and fifth anniversaries of the grant date, which was December 1, 2006. Read SEC document
April 29, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionExecutive Option (right to buy) · Derivative	11,092	$0.00 Strike: $24.74	$0.00	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · derivative · entry 21 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,908 Underlying: Common Stock, $0.10 par value · 11,092 shares Expires 2016-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: One-third of the stock option award vested on each of the third, fourth and fifth anniversaries of the grant date, which was December 1, 2006. F9 · derivative.expiration_date: One-third of the stock option award vested on each of the third, fourth and fifth anniversaries of the grant date, which was December 1, 2006. Read SEC document
April 29, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionExecutive Option (right to buy) · Derivative	25,795	$0.00 Strike: $22.73	$0.00	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · derivative · entry 20 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 25,795 shares Expires 2016-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third and fourth anniversaries of the grant date, which was March 7, 2006. F8 · derivative.expiration_date: Twenty-five percent of the stock option award vested on each of the first, second, third and fourth anniversaries of the grant date, which was March 7, 2006. Read SEC document
April 29, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	9,157	$39.97	$366,005.29	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 17 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Sigal Family Investments, LLC Disclosed balance after: 9,550 F5 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
April 29, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	18,313	$39.97	$731,970.61	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 15 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Ruth L. Sigal Irrevocable Trust Disclosed balance after: 19,099 F5 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F6 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
April 29, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	18,313	$39.97	$731,970.61	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 13 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By C. Elliott Sigal 2012 Irrevocable Trust Disclosed balance after: 19,099 F5 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F6 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
April 29, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	41,868	$39.92	$1,671,370.56	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 7 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,493 F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
April 29, 2013 Filed May 1, 2013 21:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	31,594	$39.90	$1,260,600.60	Disclosure SEC source: 0001225208-13-010911 · doc4.xml · nonDerivative · entry 6 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,361 F1 · shares: Includes shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.